Abstract
Siglecs (sialic acid-binding immunoglobulin-like lectins) are a family of receptors that bind sialic acids in specific linkages on glycoproteins and glycolipids. Siglecs play roles in immune signalling and exhibit cell-type specific expression and endocytic properties. Recent studies suggest that Siglecs are likely to function as immune checkpoints that regulate responses in cancers and inflammatory diseases. In this review, we discuss strategies to target the Siglec-sialic acid axis in human diseases, particularly cancer, and the possibility of exploiting them for therapeutic intervention.
| Original language | English |
|---|---|
| Pages (from-to) | 34-42 |
| Number of pages | 9 |
| Journal | Current Opinion in Chemical Biology |
| Volume | 62 |
| Early online date | 16 Feb 2021 |
| DOIs | |
| Publication status | Published - Jun 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Siglec
- Sialic acid
- Cancer
- Inflammation
- Immune checkpoint
ASJC Scopus subject areas
- Analytical Chemistry
- Biochemistry
Fingerprint
Dive into the research topics of 'Siglec and anti-Siglec therapies'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver